ArticleBMC microbiology2026
Stability of equol production capability is associated with the diversity of the gut microbiota of the host: a prospective cohort study.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Converting Equol Nonproducers to Producers: A Systematic Review of Randomized Clinical Trials.Food science & nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundEquol, a gut microbiota–derived metabolite of the soy isoflavone daidzein that acts mainly via estrogen receptor β, has been linked to several health benefits, including relief of menopausal symptoms and prevention of arteriosclerosis. However, little is known about how equol production capability changes over time and how these changes relate to the gut microbiota.
methodsWe analyzed data from 498 community-dwelling adults who participated annually in a health checkup between 2016 and 2019. Equol production was assessed each year using urinary equol and daidzein concentrations. Participants were classified as producers when log10(equol/daidzein) > − 1.75 and were further categorized as stable producers (equol positive in all 4 years), unstable producers (equol positive in at least 1 but not all years), or non-producers (equol negative in all years). Gut microbiota profiles were obtained from fecal samples collected in 2016 and analyzed for bacterial diversity, composition, and predicted metabolic pathways. Dietary daidzein intake was estimated using a validated brief-type self-administered diet history questionnaire.
resultsOf the 498 participants, 30.9% were stable producers, 26.1% unstable producers, and 43.0% non-producers. Stable producers showed significantly higher gut bacterial diversity than unstable producers and non-producers and a distinct microbiota composition, despite comparable daidzein intake across groups. At the genus level, differential abundance analysis indicated that taxa such as Eubacterium coprostanoligenes group, Subdoligranulum, Ruminococcus, Alistipes, and Coprococcus were enriched in stable producers, whereas Ruminococcus gnavus group, Fusobacterium, Eggerthella, Flavonifractor, and Bacteroides were more abundant in non-producers. Several genera enriched in stable producers are known short-chain fatty acid producers, whereas some genera enriched in non-producers have been reported in the context of intestinal dysbiosis and inflammation. Functional prediction analysis further indicated that stable producers had microbiota with enhanced pathways related to vitamin B and menaquinone biosynthesis, sulfate degradation, and methanogenesis.
conclusionsThe stability of equol production capability over time is associated with higher gut microbiota diversity and specific compositional and functional features. A gut microbiota composition favoring saccharolytic and butyrogenic bacteria may support sustained equol production, whereas a microbiota dominated by potentially pro-inflammatory taxa may be less conducive to equol production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.